Long COVID Labs
@longcovidlabs.bsky.social
Non-profit accelerating a cure for 100M+ people with Long COVID.
Longcovidlabs.org
Longcovidlabs.org
🚨Attn: Our long COVID Labs iOS app has been SUBMITTED from Testflight to the App Store!!! ✨
You can use our app track to your symptoms, contribute data to our Treatment Leaderboard and integrate with our ECG wearable for an additional biosignal layer. 📈
1/
You can use our app track to your symptoms, contribute data to our Treatment Leaderboard and integrate with our ECG wearable for an additional biosignal layer. 📈
1/
November 20, 2025 at 5:47 PM
🚨Attn: Our long COVID Labs iOS app has been SUBMITTED from Testflight to the App Store!!! ✨
You can use our app track to your symptoms, contribute data to our Treatment Leaderboard and integrate with our ECG wearable for an additional biosignal layer. 📈
1/
You can use our app track to your symptoms, contribute data to our Treatment Leaderboard and integrate with our ECG wearable for an additional biosignal layer. 📈
1/
Our founder Rohan spoke today at Devconnect ARG - The First Ethereum World's Fair! @devcon.org
Rohan demoed our mobile app and clinical-grade wearable, as we get ready to launch our upcoming Patient Registry! ✨
1/
Rohan demoed our mobile app and clinical-grade wearable, as we get ready to launch our upcoming Patient Registry! ✨
1/
November 19, 2025 at 9:08 PM
Our founder Rohan spoke today at Devconnect ARG - The First Ethereum World's Fair! @devcon.org
Rohan demoed our mobile app and clinical-grade wearable, as we get ready to launch our upcoming Patient Registry! ✨
1/
Rohan demoed our mobile app and clinical-grade wearable, as we get ready to launch our upcoming Patient Registry! ✨
1/
LONG COVID LABS just set a new precedent in digital health and patient-led science. For the first time, a patient registry has achieved IRB approval while using blockchain tokens to reward participants—not with speculative crypto, but with meaningful governance power and real research impact.
1/
1/
November 18, 2025 at 3:51 PM
LONG COVID LABS just set a new precedent in digital health and patient-led science. For the first time, a patient registry has achieved IRB approval while using blockchain tokens to reward participants—not with speculative crypto, but with meaningful governance power and real research impact.
1/
1/
🚨This is so important:
"After years of denial the international consensus is now shifting,” according to physicist @yaneerbaryam.bsky.social
COVID-19 is:
🛑creating a 12.9% increase in workplace absences compared to pre-pandemic
🛑causing a 2% increase in excess deaths vs. pre-pandemic
1/
"After years of denial the international consensus is now shifting,” according to physicist @yaneerbaryam.bsky.social
COVID-19 is:
🛑creating a 12.9% increase in workplace absences compared to pre-pandemic
🛑causing a 2% increase in excess deaths vs. pre-pandemic
1/
November 4, 2025 at 1:44 PM
🚨This is so important:
"After years of denial the international consensus is now shifting,” according to physicist @yaneerbaryam.bsky.social
COVID-19 is:
🛑creating a 12.9% increase in workplace absences compared to pre-pandemic
🛑causing a 2% increase in excess deaths vs. pre-pandemic
1/
"After years of denial the international consensus is now shifting,” according to physicist @yaneerbaryam.bsky.social
COVID-19 is:
🛑creating a 12.9% increase in workplace absences compared to pre-pandemic
🛑causing a 2% increase in excess deaths vs. pre-pandemic
1/
New review in The Nurse Practitioner Journal raises awareness of #SARS-Cov-2 persistence in Long COVID! ✨
LC patients are ALL too familiar with the experience of seeking out help from medical professionals - only to be met with confusion and doubt over what this disease is.
1/
LC patients are ALL too familiar with the experience of seeking out help from medical professionals - only to be met with confusion and doubt over what this disease is.
1/
November 1, 2025 at 5:29 PM
New review in The Nurse Practitioner Journal raises awareness of #SARS-Cov-2 persistence in Long COVID! ✨
LC patients are ALL too familiar with the experience of seeking out help from medical professionals - only to be met with confusion and doubt over what this disease is.
1/
LC patients are ALL too familiar with the experience of seeking out help from medical professionals - only to be met with confusion and doubt over what this disease is.
1/
📢New study out of Mass General looks at microclots in kids with Long COVID 🩸
In this study, researchers examined blood samples from 59 children with Long COVID and 14 healthy controls.
They found that the rates of microclots were SIGNIFICANTLY higher in the Long COVID patients.
1/
In this study, researchers examined blood samples from 59 children with Long COVID and 14 healthy controls.
They found that the rates of microclots were SIGNIFICANTLY higher in the Long COVID patients.
1/
October 28, 2025 at 2:28 PM
📢New study out of Mass General looks at microclots in kids with Long COVID 🩸
In this study, researchers examined blood samples from 59 children with Long COVID and 14 healthy controls.
They found that the rates of microclots were SIGNIFICANTLY higher in the Long COVID patients.
1/
In this study, researchers examined blood samples from 59 children with Long COVID and 14 healthy controls.
They found that the rates of microclots were SIGNIFICANTLY higher in the Long COVID patients.
1/
Highly recommend this review from Oba et al. on the current status of Long COVID research & treatment -- worth a read! ✨
Here, the authors outline the major hypotheses for the root causes of LC. The research community has largely been coalescing around these ideas in the last 1-2 years. 📊
1/
Here, the authors outline the major hypotheses for the root causes of LC. The research community has largely been coalescing around these ideas in the last 1-2 years. 📊
1/
October 23, 2025 at 9:35 PM
Highly recommend this review from Oba et al. on the current status of Long COVID research & treatment -- worth a read! ✨
Here, the authors outline the major hypotheses for the root causes of LC. The research community has largely been coalescing around these ideas in the last 1-2 years. 📊
1/
Here, the authors outline the major hypotheses for the root causes of LC. The research community has largely been coalescing around these ideas in the last 1-2 years. 📊
1/
📣 New Clinical Trial Compares Efficacy of Paxlovid vs. Ensitrelvir
Researchers in Thailand and Laos compared the rates of recovery from acute SARS-CoV-2 infection while patients were taking these two antiviral drugs:
1/
Researchers in Thailand and Laos compared the rates of recovery from acute SARS-CoV-2 infection while patients were taking these two antiviral drugs:
1/
October 17, 2025 at 4:27 PM
📣 New Clinical Trial Compares Efficacy of Paxlovid vs. Ensitrelvir
Researchers in Thailand and Laos compared the rates of recovery from acute SARS-CoV-2 infection while patients were taking these two antiviral drugs:
1/
Researchers in Thailand and Laos compared the rates of recovery from acute SARS-CoV-2 infection while patients were taking these two antiviral drugs:
1/
🚨New case study provides compelling evidence for a shocking conclusion:
👉Not only can the SARS-CoV-2 virus persist in the GI tract, but these chronic infections may eventually give rise to new variants of concern.
1/
👉Not only can the SARS-CoV-2 virus persist in the GI tract, but these chronic infections may eventually give rise to new variants of concern.
1/
October 10, 2025 at 11:25 AM
🚨New case study provides compelling evidence for a shocking conclusion:
👉Not only can the SARS-CoV-2 virus persist in the GI tract, but these chronic infections may eventually give rise to new variants of concern.
1/
👉Not only can the SARS-CoV-2 virus persist in the GI tract, but these chronic infections may eventually give rise to new variants of concern.
1/
✨ New study confirms tenofovir efficacy against SARS-CoV-2! (This includes Truvada!). ✨
In this study, researchers looked at two forms of the anti-HIV antiviral: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
They found both drugs effective against the virus in-vitro!
1/
In this study, researchers looked at two forms of the anti-HIV antiviral: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
They found both drugs effective against the virus in-vitro!
1/
October 1, 2025 at 5:39 PM
✨ New study confirms tenofovir efficacy against SARS-CoV-2! (This includes Truvada!). ✨
In this study, researchers looked at two forms of the anti-HIV antiviral: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
They found both drugs effective against the virus in-vitro!
1/
In this study, researchers looked at two forms of the anti-HIV antiviral: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
They found both drugs effective against the virus in-vitro!
1/
🚨Fascinating new analysis from @ucirvine.bsky.social researchers on the possible role of SARS-CoV-2 persistence in Long COVID:
The authors outline several mechanisms by which the virus could remain in the human body and cause disease.
1/
The authors outline several mechanisms by which the virus could remain in the human body and cause disease.
1/
![Figure 1 from the paper:
Caption says: Five major mechanisms by which the virus, vRNA, and viral antigens may cause multiple and different pathologies in Long COVID patients. (A) A causative factor in a large subset of patients with LC is that reservoirs of virus, viral RNA (vRNA), and/or fragments may persist in multiple sites of the body. (B) This causes chronic inflammation, overstimulating innate and adaptive immune cells, and providing continuous viral antigenic stimuli to (C) exhausted CD4+ and CD8+ T cells [31,33,34,35,36]. This may result in damage to major organ systems, leading to neurological, cardiovascular, pulmonary, muscular, and psychiatric pathologies [43,44]. (D–F) Other possible causative factors of LC include metabolic disturbances, immune dysbiosis, micro-clotting, endothelial dysfunction [38,43,45,46,47], and the reactivation of HSV-1, HSV-2, EBV, CMV, and HHV-6 [48,49]. This Figure is created using BioRender.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:j64ln53qmu6kvcof3esgtihb/bafkreicjq4wm6pts3qhm7e2qs3eivfc2pj5x2ow6axayc7f4ftpraicrk4@jpeg)
September 30, 2025 at 1:58 PM
🚨Fascinating new analysis from @ucirvine.bsky.social researchers on the possible role of SARS-CoV-2 persistence in Long COVID:
The authors outline several mechanisms by which the virus could remain in the human body and cause disease.
1/
The authors outline several mechanisms by which the virus could remain in the human body and cause disease.
1/
@amymitchellart.bsky.social says: "NIH has access to every kind of medication and test, even those not yet FDA-approved. Patients needed NIH to trial the tests and treatments their doctors can’t prescribe, or at minimum to test the effectiveness of off-label antivirals.”
6/
6/
September 12, 2025 at 1:26 AM
@amymitchellart.bsky.social says: "NIH has access to every kind of medication and test, even those not yet FDA-approved. Patients needed NIH to trial the tests and treatments their doctors can’t prescribe, or at minimum to test the effectiveness of off-label antivirals.”
6/
6/
Patients voiced nuanced criticisms.
@loscharlos.bsky.social said, “Overall if [the first] round of trials was D grade, I’d put this in B- territory.”
3/
@loscharlos.bsky.social said, “Overall if [the first] round of trials was D grade, I’d put this in B- territory.”
3/
September 12, 2025 at 1:23 AM
Patients voiced nuanced criticisms.
@loscharlos.bsky.social said, “Overall if [the first] round of trials was D grade, I’d put this in B- territory.”
3/
@loscharlos.bsky.social said, “Overall if [the first] round of trials was D grade, I’d put this in B- territory.”
3/
The NIH met this week to launch Recover TLC- the next phase of its Long COVID research.
Treatments for the next round of trials include:
👉 glucagon-like peptide-1 receptor agonists (GLP-1)
👉 stellate ganglion blocks
👉 low-dose naltrexone
👉 ⬆️ funding for an existing trial on baricitinib
1/
Treatments for the next round of trials include:
👉 glucagon-like peptide-1 receptor agonists (GLP-1)
👉 stellate ganglion blocks
👉 low-dose naltrexone
👉 ⬆️ funding for an existing trial on baricitinib
1/
September 12, 2025 at 1:19 AM
The NIH met this week to launch Recover TLC- the next phase of its Long COVID research.
Treatments for the next round of trials include:
👉 glucagon-like peptide-1 receptor agonists (GLP-1)
👉 stellate ganglion blocks
👉 low-dose naltrexone
👉 ⬆️ funding for an existing trial on baricitinib
1/
Treatments for the next round of trials include:
👉 glucagon-like peptide-1 receptor agonists (GLP-1)
👉 stellate ganglion blocks
👉 low-dose naltrexone
👉 ⬆️ funding for an existing trial on baricitinib
1/
🚨The 3rd International Long COVID Conference is coming up in November!
Check it out - details here! 👇
academicmedicaleducation.com/programs/3rd...
Check it out - details here! 👇
academicmedicaleducation.com/programs/3rd...
September 8, 2025 at 4:28 PM
🚨The 3rd International Long COVID Conference is coming up in November!
Check it out - details here! 👇
academicmedicaleducation.com/programs/3rd...
Check it out - details here! 👇
academicmedicaleducation.com/programs/3rd...
New #LongCOVID case study out!
In this study, subjects were given a new drug called IMC-2, which is a combination of the herpesvirus antiviral drug valcyclovir and celexoxib, an anti-inflammatory which is believed to also have antiviral properties.
1/
In this study, subjects were given a new drug called IMC-2, which is a combination of the herpesvirus antiviral drug valcyclovir and celexoxib, an anti-inflammatory which is believed to also have antiviral properties.
1/
September 3, 2025 at 2:33 PM
New #LongCOVID case study out!
In this study, subjects were given a new drug called IMC-2, which is a combination of the herpesvirus antiviral drug valcyclovir and celexoxib, an anti-inflammatory which is believed to also have antiviral properties.
1/
In this study, subjects were given a new drug called IMC-2, which is a combination of the herpesvirus antiviral drug valcyclovir and celexoxib, an anti-inflammatory which is believed to also have antiviral properties.
1/
LONG COVID LABS is excited to announce that we’ve awarded funds for a Long COVID patient to receive a combination treatment of Pemgarda monoclonal antibodies and Paxlovid!
1/
1/
August 19, 2025 at 11:24 PM
LONG COVID LABS is excited to announce that we’ve awarded funds for a Long COVID patient to receive a combination treatment of Pemgarda monoclonal antibodies and Paxlovid!
1/
1/
PATIENTS HAVE A VOICE:
IRB approval is also necessary so that we can compensate patients for their contribution to our research.
One of the things that makes our organization unique is that every patient who contributes to a study will receive $COVID governance tokens in return.
12/
IRB approval is also necessary so that we can compensate patients for their contribution to our research.
One of the things that makes our organization unique is that every patient who contributes to a study will receive $COVID governance tokens in return.
12/
July 29, 2025 at 3:13 PM
PATIENTS HAVE A VOICE:
IRB approval is also necessary so that we can compensate patients for their contribution to our research.
One of the things that makes our organization unique is that every patient who contributes to a study will receive $COVID governance tokens in return.
12/
IRB approval is also necessary so that we can compensate patients for their contribution to our research.
One of the things that makes our organization unique is that every patient who contributes to a study will receive $COVID governance tokens in return.
12/
WHY WE NEED IRB APPROVAL:
In the US, Institutional Review Board approval (or IRB) for short is necessary to conduct scientific research at scale.
An Institutional Review Board ensures that study participants are treated ethically, and in compliance with all applicable laws for human trials.
10/
In the US, Institutional Review Board approval (or IRB) for short is necessary to conduct scientific research at scale.
An Institutional Review Board ensures that study participants are treated ethically, and in compliance with all applicable laws for human trials.
10/
July 29, 2025 at 3:10 PM
WHY WE NEED IRB APPROVAL:
In the US, Institutional Review Board approval (or IRB) for short is necessary to conduct scientific research at scale.
An Institutional Review Board ensures that study participants are treated ethically, and in compliance with all applicable laws for human trials.
10/
In the US, Institutional Review Board approval (or IRB) for short is necessary to conduct scientific research at scale.
An Institutional Review Board ensures that study participants are treated ethically, and in compliance with all applicable laws for human trials.
10/
SUBMITTING APPLICATION FOR IRB APPROVAL
This week, our founder @rd108 is working hard on finalizing our application for Institutional Review Board approval for our Patient Registry.
This Registry will allow us to create publishable insights out of the experiments patients are running now.
3/
This week, our founder @rd108 is working hard on finalizing our application for Institutional Review Board approval for our Patient Registry.
This Registry will allow us to create publishable insights out of the experiments patients are running now.
3/
July 29, 2025 at 3:05 PM
SUBMITTING APPLICATION FOR IRB APPROVAL
This week, our founder @rd108 is working hard on finalizing our application for Institutional Review Board approval for our Patient Registry.
This Registry will allow us to create publishable insights out of the experiments patients are running now.
3/
This week, our founder @rd108 is working hard on finalizing our application for Institutional Review Board approval for our Patient Registry.
This Registry will allow us to create publishable insights out of the experiments patients are running now.
3/
WHAT WE’RE UP TO THIS WEEK:
Hey everyone! We’ve been having a very busy summer working behind the scenes to get our Patient Registry up and running.
We know so many of you are curious to know more about what we’re working on! Here’s what’s on deck for this week:
1/
Hey everyone! We’ve been having a very busy summer working behind the scenes to get our Patient Registry up and running.
We know so many of you are curious to know more about what we’re working on! Here’s what’s on deck for this week:
1/
July 29, 2025 at 3:03 PM
WHAT WE’RE UP TO THIS WEEK:
Hey everyone! We’ve been having a very busy summer working behind the scenes to get our Patient Registry up and running.
We know so many of you are curious to know more about what we’re working on! Here’s what’s on deck for this week:
1/
Hey everyone! We’ve been having a very busy summer working behind the scenes to get our Patient Registry up and running.
We know so many of you are curious to know more about what we’re working on! Here’s what’s on deck for this week:
1/
Our mission at Long COVID Labs is to accelerate evidence generation by capturing real-world #LongCOVID patient experiences, structuring them into a shared treatment registry, and funding patient access to promising therapies.
1/
1/
July 14, 2025 at 6:35 PM
Our mission at Long COVID Labs is to accelerate evidence generation by capturing real-world #LongCOVID patient experiences, structuring them into a shared treatment registry, and funding patient access to promising therapies.
1/
1/
Important article from @washingtonpost.com
👉Are our mainstream institutions failing to learn from the COVID pandemic?
“The reality is that pandemics are going to hit. They’re going to hit again,” said @zalaly.bsky.social
“It’s not a matter of if. It is a matter of when.”
1/
👉Are our mainstream institutions failing to learn from the COVID pandemic?
“The reality is that pandemics are going to hit. They’re going to hit again,” said @zalaly.bsky.social
“It’s not a matter of if. It is a matter of when.”
1/
July 10, 2025 at 2:45 PM
Important article from @washingtonpost.com
👉Are our mainstream institutions failing to learn from the COVID pandemic?
“The reality is that pandemics are going to hit. They’re going to hit again,” said @zalaly.bsky.social
“It’s not a matter of if. It is a matter of when.”
1/
👉Are our mainstream institutions failing to learn from the COVID pandemic?
“The reality is that pandemics are going to hit. They’re going to hit again,” said @zalaly.bsky.social
“It’s not a matter of if. It is a matter of when.”
1/
✨ July 2025 Updates from the Lab:✨
Today, we're announcing two major updates as part of our ongoing mission to accelerate a cure for Long COVID.
1/
Today, we're announcing two major updates as part of our ongoing mission to accelerate a cure for Long COVID.
1/
July 3, 2025 at 10:36 PM
✨ July 2025 Updates from the Lab:✨
Today, we're announcing two major updates as part of our ongoing mission to accelerate a cure for Long COVID.
1/
Today, we're announcing two major updates as part of our ongoing mission to accelerate a cure for Long COVID.
1/
We're so grateful for the volunteers who contributed healthy control blood samples for the Long COVID biomarker that we are evaluating.🙏
Their contributions help advance real-world research — and each donor will receive a $COVID token airdrop as a reward! ✨
#LongCOVID #DeSci #Biomarkers
Their contributions help advance real-world research — and each donor will receive a $COVID token airdrop as a reward! ✨
#LongCOVID #DeSci #Biomarkers
June 19, 2025 at 2:40 PM
We're so grateful for the volunteers who contributed healthy control blood samples for the Long COVID biomarker that we are evaluating.🙏
Their contributions help advance real-world research — and each donor will receive a $COVID token airdrop as a reward! ✨
#LongCOVID #DeSci #Biomarkers
Their contributions help advance real-world research — and each donor will receive a $COVID token airdrop as a reward! ✨
#LongCOVID #DeSci #Biomarkers